X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
GSK: Restructuring benefits palpable - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jul 29, 2002

    GSK: Restructuring benefits palpable

    MNC pharma major Glaxo has reported robust numbers for 2QFY03. Sales growth has been more than 20% from Rs2.5 bn to Rs 3 bn, driven mainly by focus on high growth products. The highlight of results was a sharp rise in operating margins of the company by almost 1,370 basis points. The rise in operating margins is due to combination of restructuring benefits, reduction in employee costs and focus on high margin products.

    (Rs m) 2QFY02 2QFY03 %Change
    Sales 2,268 2,722 20.0%
    Other Income 149 95 -36.2%
    Expenditure 2,089 2,133 2.1%
    Operating Profit (EBDIT) 179 589 229.0%
    Operating Profit Margin (%) 7.9% 21.6%  
    Interest - - NA
    Depreciation 47 47 -1.1%
    Profit before Tax 281 637 126.6%
    Extraordinary Income 268 (2)  
    Tax 99 231 132.7%
    Profit after Tax/(Loss) 450 405 -10.0%
    Net profit margin (%) 19.8% 14.9%  
    No. of Shares (eoy) (m) 74 74  
    Diluted Earnings per share* 24.2 21.7  
    P/E (at current price)   17.8  
    (*- annualised)      

    In a conscious decision, Glaxo discontinued its rural operations and hived off several tail end brands. A better product mix and a price rise in some of its key brands helped the company in recording a substantial rise in operating profits. The results indicate that the restructuring efforts of the company are yielding results. Improved resource allocations of marketing spend, tight control on expenses and synergies from integration and reduction in staff numbers due to manufacturing rationalisation, coupled with control on the field staff and back office headcount have helped improve profits. Glaxo's management had earlier indicated that the company intends to double its operating margins over a three year period. However, we believe that a substantial portion of increase in sales is on account of de-stocking exercise initiated by the company last year and hence may not be sustainable.

    The second quarter results have been marginally above our expectations. We expect margins to stabilise around 17-18%. Till further clarity emerges on the sustainability of the sales growth and the exact impact of the DPCO, we maintain our FY03E EPS estimate of Rs 19.8. At the current market price of Rs 386, the stock trades at 19x FY03E earnings.

     

     

    Equitymaster requests your view! Post a comment on "GSK: Restructuring benefits palpable ". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    GSK PHARMA SHARE PRICE


    Aug 22, 2017 (Close)

    TRACK GSK PHARMA

    • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    GSK PHARMA - ACTAVIS COMPARISON

    Compare Company With Charts

    COMPARE GSK PHARMA WITH

    MARKET STATS